Johnson & Johnson seeks FDA approval for CAPLYTA in bipolar mania
Johnson & Johnson (NYSE: JNJ) filed a supplemental New Drug Application with the FDA to seek approval of CAPLYTA (lumateperone) for the treatment of manic or mixed episodes associated with bipolar I disorder in adults. The submission is supported by two pivotal Phase 3 studies that showed CAPLYTA significantly reduced manic symptoms versus placebo as early as Day 3, with improvement sustained through Week 3.
Primary source
Company press release (PR Newswire), November 19, 2026
Johnson & Johnson Seeks U.S. FDA Approval for CAPLYTA in Bipolar Mania, Marking Fifth Potential Indication
Read the source: Johnson & Johnson Seeks U.S. FDA Approval for CAPLYTA in Bipolar Mania, Marking Fifth Potential Indication prnewswire.com
Machine-summarized from the source above; not independently reported. How we use automation